There are over two million new cases of breast cancer a year in the world and 0.6 million deaths. About a third of all early breast cancer cases will become metastatic even with the best [more]
Cancerworld witnessed the final consensus meeting that produced the new guidelines on advanced breast cancer. The consensus panel gathered in Lisbon during ABC5 to discuss, and sometimes to disagree. At the end, the experts voted more than 50 statements, some of them totally new for the topic [more]
When it comes to deciding the age for starting mammography, family history of cancer should count more, according to an analysis of Swedish registries just published in JAMA Oncology. To identify the risk-adapted starting age [more]
While breast cancer incidence rates are still on the rise, mortality rates keep decreasing, although at slower pace than in past. This is one of the take-home messages from Breast Cancer Statistics 2019-2020, the biennial [more]
In women diagnosed with first primary breast cancer (BC), a closer look to epigenetic might be the “ace in the hole” to better understand the link between Aspirin use and prognosis and to refine patients stratification and risk-reducing strategies. Findings from a study recently published in Cancer suggest that the [more]
A group of members of the European Parliament is promoting a manifesto “to improve services for patients in an area of still high unmet need and reduce the societal impact of breast cancer by elevating [more]
Coordinating Chair – Fatima Cardoso Chairs – Eric P. Winer, Larry Norton, Alberto Costa Co-Chairs – Giuseppe Curigliano, Shirley A. Mertz The International Consensus Conference for Advanced Breast Cancer (ABC) will take place in Lisbon, Portugal, [more]
06.12.2018 Strasbourg, France The Convention Centre and Exhibition Park (Churchill Room) 14:00 – 16:00 Chairs: E. Aribal, TR – A. Costa, IT/CH14:00 Why does the breast surgeon need ultrasound F. Meani, CH 14:20 Role of [more]
Breast cancer impacts on the way a woman sees herself and on how she is seen by her partner and society in general. It’s getting easier to talk about, but are these conversations also happening [more]
“At one year from initiation of TAM, plasma measurements show that a substantial proportion of premenopausal patients are not adequately adherent to this treatment. Poorly-adherent patients could benefit from metabolic and pharmacogenetic investigations. Identification of [more]
As a young surgeon, Bahadir Güllüoğlu was drawn to specialising in breast cancer because of the opportunities that were opening up to work closely with other types of specialists, as well as with patients and [more]
Testing for hereditary mutations that increase the risk of cancer is important for risk reduction, early detection and choice of treatment. Ephrat Levy-Lahad offers an overview of what we know ‒ and what remains uncertain [more]
Despite growing precision in understanding the biology of breast cancer, progress in extending survival of people with metastatic disease remains frustratingly slow. Median survival is only about three years, having edged up only slightly in [more]